Enliven Therapeutics, Inc. $ELVN Shares Sold by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 28.7% in the first quarter, Holdings Channel.com reports. The fund owned 929,544 shares of the company’s stock after selling 373,691 shares during the period. Pictet Asset Management Holding SA’s holdings in Enliven Therapeutics were worth $36,438,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth $83,000. Quantbot Technologies LP lifted its position in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $95,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Enliven Therapeutics

In other news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total value of $263,588.40. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at $2,233,800. This trade represents a 10.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ELVN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. HC Wainwright upped their target price on Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Guggenheim initiated coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on Enliven Therapeutics in a research report on Tuesday, June 9th. They set a “buy” rating and a $60.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.50.

Enliven Therapeutics Trading Down 0.2%

Shares of NASDAQ ELVN opened at $50.73 on Wednesday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $52.39. The company has a market cap of $3.09 billion, a PE ratio of -30.38 and a beta of 0.29. The stock has a 50 day simple moving average of $42.34 and a 200-day simple moving average of $32.98.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.